Results 71 to 80 of about 35,659,151 (163)

Angiotensin type 2 receptor is expressed in human atherosclerotic lesions

, 2008
OBJECTIVE: Expression of the angiotensin type 2 receptor (AT2-receptor) occurs in many animal models of atherosclerosis. However, its expression in human plaques and its functional role remains undetermined. This study examined AT2-receptor expression in
Fagerberg, Björn,, Bergström, Göran,, Johansson, Maria E.   +2 more
core   +1 more source

miR-155 suppresses angiotensin II type 1 receptor synthesis during placental morphogenesis

Cell Death Discovery
Several microRNAs play vital roles in placental development. miR-155 has been implicated in placental development and can directly interact with a variety of targets, including angiotensin type II receptor 1 (AT1R) (Agtr1) mRNA.
Anya L. Arthurs, Eugenie R. Lumbers, Lachlan Schofield, Celine Lees, Peck Y. Chin, Alison S. Care, Sarah A. Robertson, John E. Schjenken, Kirsty G. Pringle   +8 more
doaj   +1 more source

Angiotensin type-1 receptor and ACE2 autoantibodies in Parkinson´s disease. [PDF]

NPJ Parkinsons Dis, 2022
Labandeira CM, Pedrosa MA, Quijano A, Valenzuela R, Garrido-Gil P, Sanchez-Andrade M, Suarez-Quintanilla JA, Rodriguez-Perez AI, Labandeira-Garcia JL.   +8 more
europepmc   +1 more source

Development of selective non-peptide angiotensin II type 2 receptor agonsists

, 2010
The development of the first drug-like selective angiotensin II type 2 (AT(2)) receptor agonist (22) derived from the non-selective angiotensin II type 1 (AT(1)) receptor/AT(2) receptor agonist L-162,313 is presented.
Mathias Alterman, Alterman, Mathias,
core   +1 more source

Inhibition of Rho kinase mediates the neuroprotective effects of estrogen in the MPTP model of Parkinson's disease

Neurobiology of Disease, 2013
The mechanism by which estrogen protects dopaminergic neurons has not yet been clarified. It is not known if changes in RhoA/Rho kinase activity are involved in the enhanced vulnerability of dopaminergic neurons observed after estrogen depletion.
Ana I. Rodriguez-Perez, Antonio Dominguez-Meijide, Jose L. Lanciego, Maria J. Guerra, Jose L. Labandeira-Garcia   +4 more
doaj   +1 more source

Estrogen Metabolite 2-Methoxyestradiol Attenuates Blood Pressure in Hypertensive Rats by Downregulating Angiotensin Type 1 Receptor. [PDF]

Front Physiol, 2022
Zhang Y, Ogola BO, Iyer L, Karamyan VT, Thekkumkara T.   +4 more
europepmc   +1 more source

Angiotensin type 2 receptor actions contribute to angiotensin type 1 receptor blocker effects on kidney fibrosis

, 2009
Angiotensin type 1 (AT 1 ) receptor blocker (ARB) ameliorates progression of chronic kidney disease. Whether this protection is due solely to blockade of AT 1 , or whether diversion of angiotensin II from the AT 1 to the available AT 2 receptor, thus ...
Ma, Li-Jun, Tang, Yiwei, Zuo, Yiqin, Yang, Haichun, Han, Jee Young, Kon, Valentina, Naito, Takashi, Fogo, Agnes B.   +7 more
core   +1 more source

Rosiglitazone, a Ligand to PPARγ, Improves Blood Pressure and Vascular Function through Renin-Angiotensin System Regulation

PPAR Research, 2019
Rosiglitazone (RGZ), a peroxisome proliferator-activated receptor gamma (PPARγ) ligand, has been reported to act as insulin sensitizer and exert cardiovascular actions.
María Sánchez-Aguilar, Luz Ibarra-Lara, Leonardo Del Valle-Mondragón, María Esther Rubio-Ruiz, Alicia G. Aguilar-Navarro, Absalom Zamorano-Carrillo, Margarita del Carmen Ramírez-Ortega, Gustavo Pastelín-Hernández, Alicia Sánchez-Mendoza   +8 more
doaj   +1 more source

Angiotensin II type 1 receptor antagonists in the treatment of hypertension in elderly patients: focus on patient outcomes

, 2011
Artavazd Tadevosyan1, Eric J MacLaughlin2, Vardan T Karamyan31Departments of Medicine, Montreal Heart Institute and Université de Montréal, Montreal, QC, Canada; 2Department of Pharmacy Practice, 3Department of Pharmaceutical ...
Eric J MacLaughlin, Artavazd Tadevosyan, Vardan T Karamyan   +2 more
core  

Osteoprotegerin: a pancreatic islets dysfunction and vascular injury modulator [PDF]

, 2011
Background. Osteoprotegerin (OPG) is a soluble glycoprotein of the tumor necrosis factor (TNF) receptor superfamily, which was initially identified as a key regulator in bone turnover.
Toffoli, Barbara
core